Stacey M. Fernandes, BS

Dana-Farber Cancer Institute
Boston, MA, United States

N/A

Presentation(s):

• (1549277) Transcription factor FoxO1 Mediates Adaptive Increase in Akt Activity and Cell Survival During BCR Inhibitor Therapy in CLL

  Friday, October 6, 2023
  9:05 AM – 9:10 AM EDT

• (1553902) Mutations and translocations associated with venetoclax resistance in chronic lymphocytic leukemia (CLL)

  Friday, October 6, 2023
  1:00 PM – 1:10 PM EDT

• (1545166) METTL3 contributes to aggressive CLL via post-transcriptional regulation of splicing factor

  Saturday, October 7, 2023
  11:30 AM – 11:40 AM EDT

• (1554200) Mutations Detected in Real World Clinical Sequencing during BTK Inhibitor Treatment in Chronic Lymphocytic Leukemia (CLL)

  Sunday, October 8, 2023
  12:15 PM – 12:25 PM EDT